Business UpdateJul 22, 2026, 07:02 AM
Avalo Therapeutics CEO to Speak at BTIG Biotechnology Conference
AI Summary
Avalo Therapeutics, Inc. announced that its Chief Executive Officer, Dr. Garry Neil, will participate in the "Honing in on Hidradenitis" panel at the virtual BTIG Biotechnology Conference on July 29, 2026. Additionally, management will host one-on-one investor meetings during the conference. The company is a clinical-stage biotechnology firm developing therapeutics targeting the IL-1β pathway, with positive Phase 2 data for its lead asset, abdakibart, in hidradenitis suppurativa.
Key Highlights
- Avalo Therapeutics CEO Dr. Garry Neil to participate in BTIG Biotechnology Conference.
- Panel discussion titled "Honing in on Hidradenitis" scheduled for July 29, 2026, at 10:30 am ET.
- Management will host one-on-one investor meetings during the conference.
- Live webcasts and replays will be available on the company's investor relations website.
- Avalo Therapeutics is a clinical-stage biotech focused on IL-1β pathway therapeutics.
- Lead asset abdakibart recently reported positive Phase 2 data in hidradenitis suppurativa (HS).
- Company is also advancing AVTX-010, a next-generation anti-IL-1β monoclonal antibody.
Price Impact
More from AVTX